InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

JENA, Germany, April 14, 2023 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq:IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has completed its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $4.25 per ordinary share. The aggregate gross proceeds from the offering were approximately $40 million, before deducting the underwriting discount and offering expenses. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,411,764 additional ordinary shares at the public offering price, less the underwriting discount.

Read more at globenewswire.com